Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Diseases, Interstitial | 43 | 2023 | 235 | 11.250 |
Why?
|
Idiopathic Pulmonary Fibrosis | 35 | 2023 | 165 | 7.360 |
Why?
|
Connective Tissue Diseases | 15 | 2023 | 67 | 4.370 |
Why?
|
Autoimmune Diseases | 10 | 2017 | 241 | 2.840 |
Why?
|
Pulmonary Fibrosis | 9 | 2023 | 123 | 2.090 |
Why?
|
Tomography, X-Ray Computed | 16 | 2021 | 2601 | 1.890 |
Why?
|
Alveolitis, Extrinsic Allergic | 6 | 2021 | 34 | 1.830 |
Why?
|
Respiration Disorders | 2 | 2022 | 39 | 1.530 |
Why?
|
Occupational Exposure | 2 | 2022 | 80 | 1.530 |
Why?
|
Bronchiectasis | 3 | 2017 | 13 | 1.520 |
Why?
|
Occupational Health | 2 | 2021 | 32 | 1.470 |
Why?
|
Idiopathic Interstitial Pneumonias | 6 | 2022 | 28 | 1.320 |
Why?
|
Immunosuppressive Agents | 8 | 2023 | 977 | 1.280 |
Why?
|
Asthma | 6 | 2019 | 955 | 1.280 |
Why?
|
Lung | 18 | 2023 | 1169 | 1.210 |
Why?
|
Precision Medicine | 2 | 2023 | 395 | 1.200 |
Why?
|
Pyridones | 5 | 2020 | 51 | 1.200 |
Why?
|
Arthritis, Rheumatoid | 5 | 2022 | 166 | 1.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 243 | 1.080 |
Why?
|
Humans | 99 | 2023 | 86678 | 1.040 |
Why?
|
Respiratory Function Tests | 11 | 2021 | 136 | 1.000 |
Why?
|
Indoles | 5 | 2020 | 318 | 0.990 |
Why?
|
Autoimmunity | 6 | 2018 | 160 | 0.990 |
Why?
|
Sjogren's Syndrome | 3 | 2021 | 30 | 0.960 |
Why?
|
Disease Progression | 16 | 2023 | 1532 | 0.880 |
Why?
|
Aged | 42 | 2023 | 18423 | 0.880 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2021 | 4 | 0.820 |
Why?
|
Anti-Asthmatic Agents | 2 | 2019 | 76 | 0.820 |
Why?
|
Time-to-Treatment | 2 | 2019 | 98 | 0.810 |
Why?
|
Male | 62 | 2023 | 40988 | 0.810 |
Why?
|
Retrospective Studies | 27 | 2023 | 8496 | 0.800 |
Why?
|
Inhalation Exposure | 1 | 2021 | 28 | 0.780 |
Why?
|
Female | 54 | 2023 | 44550 | 0.760 |
Why?
|
Sarcoidosis, Pulmonary | 3 | 2016 | 17 | 0.730 |
Why?
|
Hernia, Hiatal | 2 | 2018 | 30 | 0.730 |
Why?
|
Survival Analysis | 5 | 2017 | 1538 | 0.730 |
Why?
|
Bronchial Thermoplasty | 1 | 2019 | 6 | 0.720 |
Why?
|
Middle Aged | 37 | 2021 | 25040 | 0.720 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 206 | 0.700 |
Why?
|
Aspergillus | 2 | 2017 | 9 | 0.670 |
Why?
|
Hospitalization | 3 | 2021 | 851 | 0.660 |
Why?
|
Prevalence | 9 | 2021 | 1239 | 0.660 |
Why?
|
Aspergillosis, Allergic Bronchopulmonary | 3 | 2017 | 7 | 0.640 |
Why?
|
Tacrolimus | 2 | 2017 | 373 | 0.620 |
Why?
|
Esophagus | 1 | 2018 | 102 | 0.620 |
Why?
|
Azathioprine | 2 | 2023 | 125 | 0.610 |
Why?
|
Biological Products | 1 | 2019 | 143 | 0.610 |
Why?
|
Antifungal Agents | 2 | 2014 | 117 | 0.560 |
Why?
|
Hematologic Neoplasms | 2 | 2017 | 329 | 0.560 |
Why?
|
Enzyme Inhibitors | 2 | 2016 | 639 | 0.550 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 589 | 0.550 |
Why?
|
Pulmonary Aspergillosis | 1 | 2014 | 4 | 0.510 |
Why?
|
Cohort Studies | 13 | 2023 | 2768 | 0.510 |
Why?
|
Telomere | 5 | 2023 | 108 | 0.500 |
Why?
|
Pregnancy Complications | 1 | 2017 | 336 | 0.490 |
Why?
|
Anti-Inflammatory Agents | 5 | 2020 | 339 | 0.470 |
Why?
|
Vital Capacity | 6 | 2022 | 64 | 0.460 |
Why?
|
Diagnosis, Differential | 8 | 2018 | 1566 | 0.440 |
Why?
|
Muscle, Smooth | 6 | 1996 | 354 | 0.430 |
Why?
|
Sputum | 1 | 2012 | 34 | 0.430 |
Why?
|
Prognosis | 11 | 2021 | 3680 | 0.430 |
Why?
|
Biopsy | 4 | 2022 | 1163 | 0.420 |
Why?
|
Adult | 20 | 2023 | 25659 | 0.420 |
Why?
|
Adrenal Cortex Hormones | 4 | 2017 | 263 | 0.410 |
Why?
|
Predictive Value of Tests | 4 | 2021 | 1673 | 0.400 |
Why?
|
Self Care | 1 | 2012 | 164 | 0.400 |
Why?
|
Lung Transplantation | 5 | 2020 | 175 | 0.400 |
Why?
|
United States | 11 | 2022 | 6681 | 0.390 |
Why?
|
Registries | 6 | 2022 | 703 | 0.390 |
Why?
|
Prospective Studies | 8 | 2023 | 4214 | 0.380 |
Why?
|
Dermatomyositis | 4 | 2019 | 17 | 0.380 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 1037 | 0.380 |
Why?
|
Muscle Contraction | 6 | 1996 | 284 | 0.370 |
Why?
|
Mucin-5B | 3 | 2019 | 11 | 0.350 |
Why?
|
Patient Satisfaction | 1 | 2012 | 455 | 0.340 |
Why?
|
Myositis | 2 | 2020 | 17 | 0.340 |
Why?
|
Bronchodilator Agents | 3 | 2017 | 65 | 0.330 |
Why?
|
Genome-Wide Association Study | 4 | 2023 | 1621 | 0.310 |
Why?
|
Referral and Consultation | 2 | 2021 | 328 | 0.310 |
Why?
|
Scleroderma, Systemic | 3 | 2019 | 43 | 0.310 |
Why?
|
Trachea | 5 | 1996 | 293 | 0.310 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2020 | 379 | 0.300 |
Why?
|
Respiration, Artificial | 2 | 2021 | 334 | 0.290 |
Why?
|
Severity of Illness Index | 7 | 2020 | 1802 | 0.290 |
Why?
|
Fibrosis | 4 | 2022 | 203 | 0.290 |
Why?
|
Acetylcysteine | 2 | 2018 | 69 | 0.290 |
Why?
|
Environmental Exposure | 2 | 2019 | 296 | 0.270 |
Why?
|
Quality of Life | 4 | 2023 | 1585 | 0.260 |
Why?
|
Proportional Hazards Models | 5 | 2023 | 860 | 0.250 |
Why?
|
Hypothyroidism | 2 | 2016 | 232 | 0.240 |
Why?
|
Treatment Outcome | 9 | 2020 | 7998 | 0.230 |
Why?
|
Hypertension, Pulmonary | 3 | 2018 | 346 | 0.230 |
Why?
|
Telomerase | 2 | 2020 | 55 | 0.230 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2023 | 51 | 0.230 |
Why?
|
Emphysema | 1 | 2023 | 22 | 0.230 |
Why?
|
Pulmonary Emphysema | 1 | 2023 | 30 | 0.230 |
Why?
|
Phenotype | 5 | 2020 | 2380 | 0.220 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 1992 | 0.220 |
Why?
|
Biomarkers | 4 | 2021 | 1718 | 0.220 |
Why?
|
Mediastinum | 2 | 2019 | 46 | 0.210 |
Why?
|
Patient Compliance | 2 | 2020 | 228 | 0.210 |
Why?
|
Rheumatoid Factor | 1 | 2021 | 24 | 0.210 |
Why?
|
Acetylcholine | 5 | 1996 | 176 | 0.210 |
Why?
|
Minority Groups | 1 | 2023 | 137 | 0.200 |
Why?
|
Mediastinal Diseases | 1 | 2021 | 21 | 0.200 |
Why?
|
Lymphadenopathy | 1 | 2021 | 17 | 0.200 |
Why?
|
Polymyositis | 2 | 2013 | 6 | 0.200 |
Why?
|
Survival Rate | 5 | 2020 | 1864 | 0.200 |
Why?
|
Leukotriene Antagonists | 1 | 2001 | 25 | 0.200 |
Why?
|
Multivariate Analysis | 3 | 2018 | 1001 | 0.190 |
Why?
|
Hematology | 1 | 2020 | 29 | 0.190 |
Why?
|
Societies | 1 | 2019 | 12 | 0.180 |
Why?
|
Peroxidase | 2 | 2019 | 51 | 0.180 |
Why?
|
Fever | 1 | 2020 | 125 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 861 | 0.180 |
Why?
|
C-Reactive Protein | 1 | 2020 | 190 | 0.180 |
Why?
|
Sexism | 1 | 2020 | 51 | 0.180 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2020 | 53 | 0.180 |
Why?
|
Delayed Diagnosis | 1 | 2019 | 29 | 0.180 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 267 | 0.180 |
Why?
|
Myeloblastin | 1 | 2019 | 5 | 0.180 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2019 | 21 | 0.170 |
Why?
|
Risk Assessment | 4 | 2021 | 2264 | 0.170 |
Why?
|
Lung Diseases | 1 | 2021 | 263 | 0.170 |
Why?
|
Time Factors | 5 | 2021 | 5214 | 0.170 |
Why?
|
Risk Factors | 5 | 2021 | 5420 | 0.170 |
Why?
|
Cellular Senescence | 1 | 2019 | 94 | 0.170 |
Why?
|
Antibodies, Antinuclear | 3 | 2018 | 83 | 0.170 |
Why?
|
Gastroesophageal Reflux | 2 | 2018 | 117 | 0.160 |
Why?
|
Lymph Nodes | 2 | 2019 | 533 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 4 | 2020 | 2271 | 0.160 |
Why?
|
Eosinophils | 3 | 1993 | 194 | 0.160 |
Why?
|
MicroRNAs | 1 | 2023 | 534 | 0.160 |
Why?
|
Free Radical Scavengers | 1 | 2018 | 59 | 0.160 |
Why?
|
Logistic Models | 2 | 2019 | 1188 | 0.160 |
Why?
|
Propensity Score | 1 | 2018 | 136 | 0.160 |
Why?
|
Observer Variation | 2 | 2017 | 603 | 0.150 |
Why?
|
Inducible T-Cell Co-Stimulator Protein | 1 | 2017 | 18 | 0.150 |
Why?
|
Interleukin-5 | 1 | 2017 | 36 | 0.150 |
Why?
|
Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
Host-Pathogen Interactions | 1 | 2019 | 231 | 0.150 |
Why?
|
Cause of Death | 1 | 2018 | 277 | 0.150 |
Why?
|
Pathology, Clinical | 1 | 2017 | 33 | 0.150 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2020 | 219 | 0.150 |
Why?
|
Aged, 80 and over | 7 | 2020 | 6513 | 0.150 |
Why?
|
Chronic Disease | 2 | 2017 | 973 | 0.150 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2016 | 24 | 0.150 |
Why?
|
Clinical Studies as Topic | 1 | 2016 | 4 | 0.150 |
Why?
|
Prednisone | 1 | 2017 | 258 | 0.150 |
Why?
|
Transcriptome | 1 | 2021 | 580 | 0.150 |
Why?
|
Multiple Chronic Conditions | 1 | 2016 | 5 | 0.150 |
Why?
|
Radiography | 2 | 2016 | 813 | 0.150 |
Why?
|
Respiratory Tract Infections | 1 | 2017 | 105 | 0.140 |
Why?
|
Acute Lung Injury | 1 | 2017 | 60 | 0.140 |
Why?
|
Mycophenolic Acid | 1 | 2016 | 87 | 0.140 |
Why?
|
Decision Support Systems, Clinical | 1 | 2017 | 103 | 0.140 |
Why?
|
Granuloma | 1 | 2016 | 65 | 0.140 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 141 | 0.140 |
Why?
|
Total Lung Capacity | 1 | 2016 | 5 | 0.140 |
Why?
|
Polylysine | 1 | 1996 | 33 | 0.140 |
Why?
|
Statistics as Topic | 1 | 2017 | 238 | 0.140 |
Why?
|
Biomedical Research | 1 | 2020 | 376 | 0.140 |
Why?
|
Drug Prescriptions | 1 | 2017 | 141 | 0.140 |
Why?
|
Leukocytes | 3 | 2023 | 202 | 0.140 |
Why?
|
Phospholipases A | 2 | 1993 | 45 | 0.140 |
Why?
|
Glucocorticoids | 2 | 2010 | 352 | 0.130 |
Why?
|
Cross-Over Studies | 1 | 2016 | 399 | 0.130 |
Why?
|
Ribonucleases | 1 | 1996 | 92 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
Pulmonary Artery | 1 | 2017 | 306 | 0.130 |
Why?
|
Blood Proteins | 1 | 1996 | 144 | 0.130 |
Why?
|
Physician's Role | 1 | 2017 | 179 | 0.130 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2020 | 930 | 0.130 |
Why?
|
Lymphocytes | 1 | 2017 | 464 | 0.130 |
Why?
|
Radiography, Thoracic | 2 | 2018 | 320 | 0.130 |
Why?
|
Carrier Proteins | 1 | 2018 | 673 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2020 | 1961 | 0.130 |
Why?
|
Pulmonary Medicine | 1 | 2015 | 46 | 0.130 |
Why?
|
Antigens | 1 | 2016 | 228 | 0.130 |
Why?
|
Respiratory Insufficiency | 1 | 2016 | 150 | 0.130 |
Why?
|
Guinea Pigs | 5 | 1996 | 171 | 0.130 |
Why?
|
Patient Education as Topic | 1 | 2017 | 351 | 0.120 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 268 | 0.120 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 395 | 0.120 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 1169 | 0.120 |
Why?
|
Reproducibility of Results | 2 | 2018 | 2706 | 0.120 |
Why?
|
Antifibrinolytic Agents | 1 | 2014 | 30 | 0.120 |
Why?
|
Macrolides | 1 | 2013 | 31 | 0.120 |
Why?
|
Adalimumab | 1 | 2014 | 80 | 0.120 |
Why?
|
Phenylpropionates | 1 | 2013 | 10 | 0.120 |
Why?
|
Endothelin A Receptor Antagonists | 1 | 2013 | 11 | 0.110 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 895 | 0.110 |
Why?
|
Pyridazines | 1 | 2013 | 22 | 0.110 |
Why?
|
Pharmacogenetics | 1 | 2017 | 434 | 0.110 |
Why?
|
Comorbidity | 1 | 2017 | 944 | 0.110 |
Why?
|
Bronchi | 2 | 2013 | 229 | 0.110 |
Why?
|
Exercise Therapy | 1 | 2013 | 80 | 0.110 |
Why?
|
Sarcoidosis | 1 | 2013 | 71 | 0.110 |
Why?
|
Longitudinal Studies | 3 | 2022 | 1019 | 0.110 |
Why?
|
Airway Management | 1 | 2013 | 46 | 0.110 |
Why?
|
Chicago | 1 | 2017 | 1380 | 0.110 |
Why?
|
Peptides | 1 | 1996 | 639 | 0.110 |
Why?
|
Canada | 2 | 2023 | 204 | 0.100 |
Why?
|
Serotonin | 1 | 1993 | 218 | 0.100 |
Why?
|
Child | 1 | 2023 | 6928 | 0.100 |
Why?
|
Palliative Care | 1 | 2013 | 257 | 0.100 |
Why?
|
Pseudomonas aeruginosa | 1 | 2012 | 194 | 0.090 |
Why?
|
Voriconazole | 1 | 2010 | 17 | 0.090 |
Why?
|
Models, Genetic | 1 | 2015 | 926 | 0.090 |
Why?
|
Young Adult | 3 | 2017 | 5980 | 0.090 |
Why?
|
In Vitro Techniques | 5 | 1996 | 989 | 0.090 |
Why?
|
Pregnancy | 1 | 2017 | 2894 | 0.090 |
Why?
|
Gene Expression Profiling | 1 | 2015 | 1384 | 0.090 |
Why?
|
Immunoglobulin E | 1 | 2010 | 144 | 0.090 |
Why?
|
Triazoles | 1 | 2010 | 96 | 0.090 |
Why?
|
Case-Control Studies | 3 | 2020 | 1807 | 0.090 |
Why?
|
Lung Neoplasms | 2 | 2018 | 2262 | 0.090 |
Why?
|
Disease Susceptibility | 1 | 2010 | 193 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2010 | 132 | 0.090 |
Why?
|
Europe | 2 | 2023 | 309 | 0.090 |
Why?
|
Surveys and Questionnaires | 2 | 2021 | 2504 | 0.080 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 747 | 0.080 |
Why?
|
Antibodies, Monoclonal | 2 | 2014 | 1376 | 0.080 |
Why?
|
Pyrimidines | 1 | 2010 | 370 | 0.080 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 728 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2011 | 246 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2016 | 2207 | 0.070 |
Why?
|
3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 8 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2013 | 878 | 0.070 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2006 | 30 | 0.070 |
Why?
|
Nitriles | 1 | 2006 | 149 | 0.070 |
Why?
|
Eicosapentaenoic Acid | 1 | 2023 | 19 | 0.060 |
Why?
|
Proprotein Convertases | 1 | 2023 | 26 | 0.060 |
Why?
|
Tobacco Smoking | 1 | 2023 | 25 | 0.060 |
Why?
|
Societies, Medical | 2 | 2019 | 573 | 0.060 |
Why?
|
Carbon Monoxide | 1 | 2023 | 90 | 0.060 |
Why?
|
Australasia | 1 | 2023 | 4 | 0.060 |
Why?
|
Churg-Strauss Syndrome | 1 | 2003 | 9 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2014 | 1824 | 0.060 |
Why?
|
Lung Volume Measurements | 1 | 2022 | 19 | 0.060 |
Why?
|
Serine Endopeptidases | 1 | 2023 | 145 | 0.050 |
Why?
|
Antacids | 1 | 2022 | 4 | 0.050 |
Why?
|
North America | 1 | 2023 | 180 | 0.050 |
Why?
|
Genetic Variation | 2 | 2019 | 1351 | 0.050 |
Why?
|
Cough | 1 | 2022 | 54 | 0.050 |
Why?
|
Bronchoalveolar Lavage | 1 | 2021 | 26 | 0.050 |
Why?
|
Pulmonologists | 1 | 2021 | 6 | 0.050 |
Why?
|
Proteomics | 1 | 2023 | 211 | 0.050 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 17 | 0.050 |
Why?
|
Radiologists | 1 | 2021 | 46 | 0.050 |
Why?
|
Early Diagnosis | 1 | 2021 | 132 | 0.050 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2001 | 78 | 0.050 |
Why?
|
Biology | 1 | 2020 | 50 | 0.050 |
Why?
|
Chitinase-3-Like Protein 1 | 1 | 2020 | 9 | 0.050 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2020 | 11 | 0.050 |
Why?
|
CA-125 Antigen | 1 | 2020 | 22 | 0.050 |
Why?
|
Chemokine CXCL13 | 1 | 2020 | 15 | 0.050 |
Why?
|
Pulmonary Surfactant-Associated Protein D | 1 | 2020 | 7 | 0.050 |
Why?
|
Carcinoma, Small Cell | 1 | 2001 | 134 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2020 | 118 | 0.050 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 56 | 0.050 |
Why?
|
Spindle Apparatus | 1 | 2020 | 65 | 0.040 |
Why?
|
Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 3 | 0.040 |
Why?
|
Animals | 8 | 2017 | 26590 | 0.040 |
Why?
|
Exoribonucleases | 1 | 2019 | 9 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 348 | 0.040 |
Why?
|
Telomere-Binding Proteins | 1 | 2019 | 14 | 0.040 |
Why?
|
Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 4 | 0.040 |
Why?
|
Vasculitis | 1 | 2019 | 39 | 0.040 |
Why?
|
Diagnostic Tests, Routine | 1 | 2019 | 62 | 0.040 |
Why?
|
Ireland | 1 | 2019 | 9 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2021 | 350 | 0.040 |
Why?
|
DNA Helicases | 1 | 2019 | 79 | 0.040 |
Why?
|
GTPase-Activating Proteins | 1 | 2019 | 65 | 0.040 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2019 | 141 | 0.040 |
Why?
|
Rheumatology | 1 | 2019 | 29 | 0.040 |
Why?
|
Patient Discharge | 1 | 2021 | 300 | 0.040 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 182 | 0.040 |
Why?
|
United Kingdom | 1 | 2019 | 164 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 54 | 0.040 |
Why?
|
Patient Readmission | 1 | 2021 | 329 | 0.040 |
Why?
|
Signal Transduction | 2 | 2020 | 3243 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2020 | 388 | 0.040 |
Why?
|
Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
Microscopic Angioscopy | 1 | 2016 | 1 | 0.040 |
Why?
|
Bleomycin | 1 | 2017 | 98 | 0.040 |
Why?
|
Sex Factors | 1 | 2020 | 1055 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2023 | 2379 | 0.040 |
Why?
|
Treatment Failure | 1 | 2017 | 286 | 0.040 |
Why?
|
Cytochalasin B | 2 | 1993 | 19 | 0.040 |
Why?
|
Lipoxygenase Inhibitors | 2 | 1993 | 33 | 0.040 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 2 | 1993 | 39 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2017 | 369 | 0.040 |
Why?
|
Syndrome | 1 | 2017 | 446 | 0.040 |
Why?
|
Eosinophil Granule Proteins | 1 | 1996 | 20 | 0.030 |
Why?
|
Th2 Cells | 1 | 2017 | 146 | 0.030 |
Why?
|
Cations | 1 | 1996 | 30 | 0.030 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 1996 | 40 | 0.030 |
Why?
|
Atropine | 1 | 1996 | 59 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 1621 | 0.030 |
Why?
|
Medication Therapy Management | 1 | 2016 | 16 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 937 | 0.030 |
Why?
|
Phospholipases A2 | 2 | 1993 | 44 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 853 | 0.030 |
Why?
|
Acetophenones | 2 | 1993 | 27 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 456 | 0.030 |
Why?
|
Inflammation | 1 | 2021 | 923 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2016 | 45 | 0.030 |
Why?
|
Gene Expression | 1 | 2020 | 1284 | 0.030 |
Why?
|
RNA | 1 | 2019 | 560 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2015 | 196 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2017 | 2819 | 0.030 |
Why?
|
Regression Analysis | 1 | 2015 | 596 | 0.030 |
Why?
|
Disease Management | 1 | 2016 | 327 | 0.030 |
Why?
|
Autoantibodies | 1 | 2015 | 267 | 0.030 |
Why?
|
Risk | 1 | 2015 | 674 | 0.030 |
Why?
|
Illinois | 1 | 2015 | 462 | 0.030 |
Why?
|
Blood Cells | 1 | 1993 | 33 | 0.030 |
Why?
|
Kinetics | 2 | 1993 | 1513 | 0.030 |
Why?
|
Muscle Tonus | 1 | 1993 | 19 | 0.030 |
Why?
|
Phenyl Ethers | 1 | 1993 | 13 | 0.030 |
Why?
|
Acetamides | 1 | 1993 | 26 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 689 | 0.030 |
Why?
|
Fetal Blood | 1 | 1993 | 90 | 0.030 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1993 | 137 | 0.030 |
Why?
|
Erythropoietin | 1 | 1993 | 91 | 0.030 |
Why?
|
Preoperative Period | 1 | 2013 | 91 | 0.030 |
Why?
|
4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine | 1 | 1992 | 4 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2001 | 1464 | 0.030 |
Why?
|
Advance Care Planning | 1 | 2013 | 43 | 0.030 |
Why?
|
Eicosanoids | 1 | 1992 | 16 | 0.030 |
Why?
|
Administration, Oral | 1 | 2014 | 684 | 0.030 |
Why?
|
Receptors, Muscarinic | 1 | 1992 | 49 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2017 | 1924 | 0.030 |
Why?
|
Electric Stimulation | 1 | 1993 | 347 | 0.030 |
Why?
|
Epithelium | 1 | 1993 | 319 | 0.030 |
Why?
|
Bronchial Hyperreactivity | 1 | 1992 | 77 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2013 | 278 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2001 | 1075 | 0.030 |
Why?
|
Manometry | 1 | 2011 | 43 | 0.030 |
Why?
|
Terminal Care | 1 | 2013 | 130 | 0.020 |
Why?
|
Platelet Activating Factor | 1 | 1991 | 53 | 0.020 |
Why?
|
Pulmonary Circulation | 1 | 1991 | 86 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 3095 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2017 | 2231 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2011 | 493 | 0.020 |
Why?
|
Genomics | 1 | 2015 | 720 | 0.020 |
Why?
|
Body Water | 1 | 1989 | 35 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2013 | 394 | 0.020 |
Why?
|
Body Temperature Regulation | 1 | 1989 | 56 | 0.020 |
Why?
|
Mutation | 1 | 2020 | 3968 | 0.020 |
Why?
|
Respiratory Physiological Phenomena | 1 | 1989 | 48 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 1921 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 2357 | 0.020 |
Why?
|
Decision Making | 1 | 2013 | 642 | 0.020 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2006 | 9 | 0.020 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2006 | 17 | 0.020 |
Why?
|
Carboxylic Acids | 1 | 2006 | 17 | 0.020 |
Why?
|
Forced Expiratory Volume | 1 | 2006 | 122 | 0.020 |
Why?
|
Mice | 1 | 2017 | 11356 | 0.010 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2001 | 44 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2006 | 3642 | 0.010 |
Why?
|
Leukotriene C4 | 1 | 1993 | 21 | 0.010 |
Why?
|
Methacholine Chloride | 1 | 1993 | 64 | 0.010 |
Why?
|
Quinacrine | 1 | 1993 | 14 | 0.010 |
Why?
|
Eosinophil Peroxidase | 1 | 1993 | 14 | 0.010 |
Why?
|
SRS-A | 1 | 1993 | 27 | 0.010 |
Why?
|
Centrifugation, Density Gradient | 1 | 1993 | 112 | 0.010 |
Why?
|
Peroxidases | 1 | 1993 | 34 | 0.010 |
Why?
|
Arachidonic Acid | 1 | 1993 | 63 | 0.010 |
Why?
|
Superoxides | 1 | 1993 | 73 | 0.010 |
Why?
|
Cell Separation | 1 | 1993 | 196 | 0.010 |
Why?
|
Tachyphylaxis | 1 | 1991 | 14 | 0.010 |
Why?
|
Pyridinium Compounds | 1 | 1991 | 10 | 0.010 |
Why?
|
Blood | 1 | 1991 | 69 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1991 | 312 | 0.010 |
Why?
|
Homeostasis | 1 | 1993 | 409 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 1991 | 197 | 0.010 |
Why?
|
Perfusion | 1 | 1991 | 203 | 0.010 |
Why?
|
Respiratory System | 1 | 1989 | 116 | 0.010 |
Why?
|
Dogs | 1 | 1989 | 686 | 0.010 |
Why?
|
Rats | 1 | 1991 | 3992 | 0.000 |
Why?
|